Our Mission

Participating as a strategic partner in the global ecosystem for the transformative research, development and manufacture of safe and effective mRNA vaccines for global public health and pandemic preparedness and prevention.

The new mRNA Vaccine Factory in the UK for Global Pandemic Preparedness and Prevention

With a focus on partnership and open science we are developing the future of mRNA Vaccines through shared scientific expertise, agility and innovation, for the COVID-19 pandemic, infectious disease and long-term sustained pandemic preparedness. Our vision is to create a Freedom to Operate (FTO) ecosystem for mRNA Vaccines, The UKvax Factory, where research and development will co-exist with established GMP manufacturing at large-scale, small-scale and micro-scale.

Our Focus

UKvax Factory focus for 2021 is rapid long-term growth, achieved through short- and long-term pandemic strategies. Our GMP manufacturing solution will support the current COVID-19 pandemic with industrial scale infrastructure. We plan to deliver sustained pandemic preparedness through open science research and development in The UK, Scandinavia and the EU. As a social enterprise our goal is to provide affordable solutions to deliver high impact for global public health. Our unique export products and services in development include:


Developing and manufacturing of mRNA vaccines with Lipidnanoparticle (LNP) delivery for COVID-19, infectious diseases and disease therapeutics


Fill-finishing for Vaccines and Therapeutics for COVID-19 and Pandemic Preparedness


Developing and manufacturing advanced, low cost, rapid diagnostics for viral infections, including COVID-19


Developing and manufacturing of treatments for infectious disease and pandemic preparedness (long term growth phase)

mRNA Vaccine Platform technology, with industrial scale GMP manufacturing, for transformative biomedical innovation opportunities with UKvax Factory.

Over the past 60 years, scientists have learned how to use mRNA to develop a new category of medicines which have recently been proven to be transformative for preventing infection and disease in the COVID-19 pandemic.

Norvax, with the mRNA UCV Consortium and Norsk Vaksinefabrikk, is leveraging the fundamental role that mRNA plays in protein synthesis to develop the mRNA Universal Coronavirus Vaccine (mRNA UCV) for the SARS-CoV-2 virus which causes COVID-19 disease. Norvax and the mRNA UCV Consortium are “programming” the harmless “spike” portion of the SARS-CoV-2 virus for the planned manufacturing into mRNA molecules with encapsulation into Lipid nanoparticles (LNPs), for an mRNA UCV product, to stimulate immunity in the event of SARS-CoV-2 infection by so-called “Variants of Concern” including the Alpha, Beta, Gamma, Delta. Industrial scale production of mRNA UCV is planned to be delivered by UKvax Factory in 2022/23.

Industrial Scale Manufacturing and Fill-finish

UKvax Factory fill-finish production line is capable of 36,000 2R vials per hour.

In a 10R vial, at 0.5ml per dose, UKvax Factory capacity is planned to be up to 289,000,000 vaccine doses per month, representing an emergency pandemic preparedness priority fill-finish capacity of up to 5 million vaccine doses in less than 24 hours from delivery of bulk vaccine supply.

Norvax focus is on long-term sustained growth and business development in the international biopharmaceutical industry. The Norvax growth plan will create high value employment opportunities.

The mRNA Vaccine Platform

Starting with the mRNA UCV flagship product development, Norvax, UKvax Factory, USvax Factory, mRNA UCV Consortium, and members of Vaxcomm – The Vaccine FTO Commons, are openly supported to apply the mRNA Vaccine Platform to develop novel mRNA vaccines
for infectious disease, therapeutics and cancers.

Learn More

Members of the mRNA UCV Consortium, and VaxComm – The Vaccine FTO Commons, are openly supported to apply the mRNA Vaccine Platform by Norvax to develop safe and effective novel mRNA vaccines for infectious diseases, therapeutics and cancers.


Learn More About Us

Visit Website
Visit Website
Visit Website
Visit Website
Visit Website